Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)
Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Jonathon B. Cohen(Emory University), Anupama Kalsekar(Genmab (United States)), Thomas M. Habermann(Mayo Clinic in Arizona), Lynn Huynh(Northern Arizona University), Rajesh Kamalakar(AbbVie (United States)), Peter Martin(Northwestern University), Izidore S. Lossos(University of Miami), Monika Jun(Genmab (United States)), Ruitao Lin(The University of Texas MD Anderson Cancer Center), Dai Chihara(The University of Texas MD Anderson Cancer Center), Ramya Ramasubramanian(Analysis Group (United States)), Matthew J. Maurer(Mayo Clinic in Arizona), Chi Gao(North China University of Science and Technology Affiliated Hospital), Tongsheng Wang(Genmab (United States)), Mei Sheng Duh(Analysis Group (United States)), Amy Ayers(The University of Texas MD Anderson Cancer Center), Carla Casulo(University of Rochester Medical Center), Brad S. Kahl(UW Health University Hospital), James R. Cerhan(Mayo Clinic), Clark R. Andersen(The University of Texas MD Anderson Cancer Center), Brian K. Link(University of Iowa), Ziyi Li(The University of Texas MD Anderson Cancer Center), Yucai Wang(Mayo Clinic), Alex Mutebi(Genmab (United States)), Melissa C. Larson(Mayo Clinic), Anthony Wang(University of California, Los Angeles)
Cited by 7
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k